Among potential molecules, anti-TGFbeta2 neutralizing antibodies and small molecules inhibiting pERK 1/2, Smads and PI-3K signaling have been proposed and some of them are being tested in clinical trials for LMNA-related cardiomyopathy (https://www.clinicaltrials.gov/ct2/show/NCT03439514, accessed on 16 April 2021) [145,147]. Here, TGFB2 is linked to cardiomyopathy.